Zobrazeno 1 - 10
of 112
pro vyhledávání: '"Sandrine, Boyault"'
Autor:
Armelle Dufresne, Valéry Attignon, Anthony Ferrari, Laurie Tonon, Sandrine Boyault, Séverine Tabone‐Eglinger, Philippe Cassier, Olivier Trédan, Nadège Corradini, Armelle Vinceneux, Aurélie Swalduz, Alain Viari, Sylvie Chabaud, David Pérol, Jean Yves Blay, Pierre Saintigny
Publikováno v:
Cancer Medicine, Vol 13, Iss 7, Pp n/a-n/a (2024)
Abstract Introduction The objective was to determine the added value of comprehensive molecular profile by whole‐exome and RNA sequencing (WES/RNA‐Seq) in advanced and refractory cancer patients who had no molecular‐based treatment recommendati
Externí odkaz:
https://doaj.org/article/9b729f0973334b92809d58a905b67735
Autor:
Olivier Trédan, Maud Toulmonde, Christophe Le Tourneau, Laure Montane, Antoine Italiano, Isabelle Ray-Coquard, Christelle De La Fouchardière, François Bertucci, Anthony Gonçalves, Carlos Gomez-Roca, Benoit You, Valéry Attignon, Sandrine Boyault, Philippe A. Cassier, Armelle Dufresne, Séverine Tabone-Eglinger, Alain Viari, Emilie Sohier, Maud Kamal, Gwenaël Garin, Jean-Yves Blay, David Pérol
Publikováno v:
Cancers, Vol 15, Iss 13, p 3441 (2023)
Background: MOST-plus is a multicenter, randomized, open-label, adaptive Phase II trial evaluating the clinical benefit of targeted treatments matched to molecular alteration in advanced/metastatic solid tumors. Sorafenib was tested on patients with
Externí odkaz:
https://doaj.org/article/9252af336131459388bd3c930b52ed6c
Autor:
Philippe A. Cassier, Clémentine Peyramaure, Valery Attignon, Lauriane Eberst, Camille Pacaud, Sandrine Boyault, Françoise Desseigne, Mathieu Sarabi, Pierre Guibert, Pauline Rochefort, Nathalie Marques, Michel Rivoire, Aurélien Dupré, Patrice Peyrat, Catherine Terret, Isabelle Ray-Coquard, Clélia Coutzac, David Pérol, Jean-Yves Blay, Olivier Trédan, Christelle de la Fouchardière
Publikováno v:
Translational Oncology, Vol 15, Iss 1, Pp 101266- (2022)
Background: Chemotherapy, anti-HER2 and PD-1 antibodies are standard treatments but only a minority of patients derive long-term benefit from these agents. Methods: In this report we describe the mutational landscape and outcome of patients with gast
Externí odkaz:
https://doaj.org/article/af51f8a698dc4ce7a25e81ac463e3700
Autor:
Nicolas Alcala, Lise Mangiante, Nolwenn Le-Stang, Corinne E. Gustafson, Sandrine Boyault, Francesca Damiola, Karine Alcala, Marie Brevet, Françoise Thivolet-Bejui, Cécile Blanc-Fournier, Jean-Philippe Le Rochais, Gaëtane Planchard, Nathalie Rousseau, Diane Damotte, Jean Claude Pairon, Marie Christine Copin, Arnaud Scherpereel, Eric Wasielewski, Laurence Wicquart, Stéphanie Lacomme, Jean-Michel Vignaud, Gaspard Ancelin, Cécile Girard, Christine Sagan, Christelle Bonnetaud, Véronique Hofman, Paul Hofman, Jérôme Mouroux, Vincent Thomas de Montpreville, Estelle Clermont-Taranchon, Julien Mazieres, Isabelle Rouquette, Hugues Begueret, Jean-Yves Blay, Sylvie Lantuejoul, Raphael Bueno, Christophe Caux, Nicolas Girard, James D. McKay, Matthieu Foll, Françoise Galateau-Salle, Lynnette Fernandez-Cuesta
Publikováno v:
EBioMedicine, Vol 48, Iss , Pp 191-202 (2019)
Background: Malignant Pleural Mesothelioma (MPM) is an aggressive disease related to asbestos exposure, with no effective therapeutic options. Methods: We undertook unsupervised analyses of RNA-sequencing data of 284 MPMs, with no assumption of discr
Externí odkaz:
https://doaj.org/article/2c7c70f40fc542e08e13ea5e57802c71
Autor:
Anne-Sophie Sertier, Anthony Ferrari, Roxane M. Pommier, Isabelle Treilleux, Sandrine Boyault, Mojgan Devouassoux-Shisheboran, Janice Kielbassa, Emilie Thomas, Laurie Tonon, Vincent Le Texier, Amandine Charreton, Anne-Pierre Morel, Anne Floquet, Florence Joly, Dominique Berton-Rigaud, Gwenaël Ferron, Laurent Arnould, Sabrina Croce, Guillaume Bataillon, Pierre Saintigny, Eliane Mery-Lamarche, Christine Sagan, Aruni P. Senaratne, Ivo G. Gut, Fabien Calvo, Alain Viari, Maria Ouzounova, Isabelle Ray-Coquard, Alain Puisieux
Publikováno v:
Cancer Research Communications. 3:830-841
Gynecologic carcinosarcomas (CS) are biphasic neoplasms composed of carcinomatous (C) and sarcomatous (S) malignant components. Because of their rarity and histologic complexity, genetic and functional studies on CS are scarce and the mechanisms of i
Autor:
Jebrane Bouaoud, Jean-Philippe Foy, Antonin Tortereau, Lucas Michon, Vincent Lavergne, Nicolas Gadot, Sandrine Boyault, Julie Valantin, Geneviève De Souza, Philippe Zrounba, Chloé Bertolus, Nathalie Bendriss-Vermare, Pierre Saintigny
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Understanding the dynamics of the immune microenvironment is critical to the development of immuno-based strategies for the prevention of oral potentially malignant disorders transformation to oral squamous cell carcinoma (OSCC). We used laser captur
Externí odkaz:
https://doaj.org/article/a3fb5b680a9e4f0ea45c23935f4e9ad5
Autor:
Fabrice Andre, Thomas Filleron, Maud Kamal, Fernanda Mosele, Monica Arnedos, Florence Dalenc, Marie-Paule Sablin, Mario Campone, Hervé Bonnefoi, Claudia Lefeuvre-Plesse, William Jacot, Florence Coussy, Jean-Marc Ferrero, George Emile, Marie-Ange Mouret-Reynier, Jean-Christophe Thery, Nicolas Isambert, Alice Mege, Philippe Barthelemy, Benoit You, Nawale Hajjaji, Ludovic Lacroix, Etienne Rouleau, Alicia Tran-Dien, Sandrine Boyault, Valery Attignon, Pierre Gestraud, Nicolas Servant, Christophe Le Tourneau, Linda Larbi Cherif, Isabelle Soubeyran, Filippo Montemurro, Alain Morel, Amelie Lusque, Marta Jimenez, Alexandra Jacquet, Anthony Gonçalves, Thomas Bachelot, Ivan Bieche
Publikováno v:
Nature
Nature, 2022, 610 (7931), pp.343-348. ⟨10.1038/s41586-022-05068-3⟩
Nature, 2022, 610 (7931), pp.343-348. ⟨10.1038/s41586-022-05068-3⟩
Cancer progression is driven in part by genomic alterations
Autor:
Fabrice Barlesi, Pascale Tomasini, Maryam Karimi, Stefan Michiels, Judith Raimbourg, Catherine Daniel, Henri Janicot, Anne Madroszyk, Clarisse Audigier-Valette, Elisabeth Quoix, Julien Mazieres, Denis Moro-Sibilot, Eric Dansin, Olivier Molinier, Hugues Morel, Eric Pichon, Alexis Cortot, Josiane Otto, François Chomy, Pierre-Jean Souquet, Nicolas Cloarec, Etienne Giroux-Leprieur, Ivan Bieche, Ludovic Lacroix, Sandrine Boyault, Valery Attignon, Isabelle Soubeyran, Alain Morel, Alicia Tran-Dien, Alexandra Jacquet, Filippo Gustavo Dall'Olio, Marta Jimenez, Jean-Charles Soria, Benjamin Besse
Publikováno v:
Clinical Cancer Research. 28:4018-4026
Purpose: Targeted therapies (TT) and immune checkpoint blockers (ICB) have revolutionized the approach to non–small cell lung cancer (NSCLC) treatment in the era of precision medicine. Their impact as switch maintenance therapy based on molecular c
Autor:
Sandra Ortiz-Cuaran, Aurélie Swalduz, Jean-Philippe Foy, Solène Marteau, Anne-Pierre Morel, Frédérique Fauvet, Geneviève De Souza, Lucas Michon, Maxime Boussageon, Nicolas Gadot, Marion Godefroy, Sophie Léon, Antonin Tortereau, Nour-El-Houda Mourksi, Camille Leonce, Marie Alexandra Albaret, Anushka Dongre, Béatrice Vanbervliet, Marie Robert, Laurie Tonon, Roxane M. Pommier, Véronique Hofman, Valéry Attignon, Sandrine Boyault, Carole Audoynaud, Jessie Auclair, Fanny Bouquet, Qing Wang, Christine Ménétrier-Caux, Maurice Pérol, Christophe Caux, Paul Hofman, Sylvie Lantuejoul, Alain Puisieux, Pierre Saintigny
Publikováno v:
European Journal of Cancer. 169:106-122
Epithelial-to-mesenchymal transition (EMT) is associated with tumor aggressiveness, drug resistance, and poor survival in non-small cell lung cancer (NSCLC) and other cancers. The identification of immune-checkpoint ligands (ICPLs) associated with NS
Autor:
Pérol, Olivier Trédan, Maud Toulmonde, Christophe Le Tourneau, Laure Montane, Antoine Italiano, Isabelle Ray-Coquard, Christelle De La Fouchardière, François Bertucci, Anthony Gonçalves, Carlos Gomez-Roca, Benoit You, Valéry Attignon, Sandrine Boyault, Philippe A. Cassier, Armelle Dufresne, Séverine Tabone-Eglinger, Alain Viari, Emilie Sohier, Maud Kamal, Gwenaël Garin, Jean-Yves Blay, David
Publikováno v:
Cancers; Volume 15; Issue 13; Pages: 3441
Background: MOST-plus is a multicenter, randomized, open-label, adaptive Phase II trial evaluating the clinical benefit of targeted treatments matched to molecular alteration in advanced/metastatic solid tumors. Sorafenib was tested on patients with